Chronic viral hepatitis C micro-elimination program using telemedicine in Guigang city

被引:1
|
作者
Lv, Riying [1 ]
Lu, Yanmeng [1 ]
Xiang, Wenyao [1 ]
Meng, Menglan [1 ]
Li, Shixiong [1 ,2 ]
机构
[1] Guigang City Peoples Hosp, Dept Infect Dis, Guigang, Guangxi, Peoples R China
[2] Guigang City Peoples Hosp, Dept Infect Dis, Guigang 537100, Guangxi, Peoples R China
关键词
ageing; Guigang; HCV; microclearance; telemedicine; NATURAL-HISTORY; EPIDEMIOLOGY; INFECTION; OUTCOMES;
D O I
10.1111/jvh.13922
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Hepatitis C virus (HCV) represents a formidable menace to human health, necessitating urgent attention. The objective of this study was to assess the efficacy and safety of HCV health management in the city of Guigang which consists of five districts, employing a comprehensive multi-modal approach. The study systematically carried out HCV screening in Guigang city which consists of five districts, such as Gangbei District, Gangnan District, Guiping District, Qintang District, and Pingnan District from 1 January 2016 to 30 December 2022. The target population consisted of individuals residing in these aforementioned districts, falling within the age range of 30-75 years. A multidisciplinary HCV management team was established to deliver anti-HCV screening, diagnosis, and direct-acting antiviral (DAA) therapy. The primary outcome of interest was the achievement of sustained virologic response (SVR). A total of 2489 individuals were included as the target population, with 1694 individuals residing in Gangbei District, 202 in Gangnan District, 111 in Qintang District, 167 in Pingnan District, and 315 in Guiping District. Out of these individuals, 2478 were subjected to anti-HCV screening. The screening rates varied across the districts, ranging from a peak of 99.55% in Guigang City to a nadir of 98.41% in Guiping District. Remarkably, within Guigang City, a noteworthy enhancement was observed in the HCV-RNA diagnosis rate from 23.4% prior to program implementation to a remarkable 100% following 7 years of intervention and management. Furthermore, the diagnosis and treatment coordination rate experienced a substantial improvement, rising from 26.8% before program inception to 80%. Importantly, a total of 1180 individuals affected by hepatitis C were successfully cured, equating to a 100% cure rate. Logistic regression analysis revealed a significant association between serological status and factors such as Aging, bilirubin, and glutamic oxalacetic transaminase. The findings from our investigation unveil a pioneering HCV management model, exemplified by the Guigang model, which has contributed crucially to HCV microclearance efforts and serves as an invaluable reference for future initiatives.
引用
收藏
页码:208 / 215
页数:8
相关论文
共 50 条
  • [1] Chronic viral hepatitis C micro-elimination program using telemedicine. The Mexican experience
    Perez Hernandez, Jose Luis
    Higuera de la Tijera, Ma de Fatima
    Arce Salinas, Cesar Alejandro
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2021, 113 (08) : 624 - 624
  • [2] Chronic viral hepatitis C micro-elimination program using telemedicine. The Mexican experience
    Perez Hernandez, Jose Luis
    Lehmann Mendoza, Rodolfo
    Luna Martinez, Javier
    Torres Roldan, Jose Fernando
    Chaidez Rosales, Pedro Armando
    Martinez Arredondo, Hilario Ascencion
    Rebollar Gonzalez, Veronica
    de la Cruz Silva, Lourdes
    Santana Vargas, Daniel
    Higuera de la Tijera, Maria de Fatima
    Arce Salinas, C. Alejandro
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2021, 113 (06) : 432 - 435
  • [3] Micro-elimination of hepatitis C virus
    Hollande, Clemence
    Parlati, Lucia
    Pol, Stanislas
    LIVER INTERNATIONAL, 2020, 40 : 67 - 71
  • [4] A micro-elimination approach to addressing hepatitis C in Turkey
    Idilman, Ramazan
    Razavi, Homie
    Robbins-Scott, Sarah
    Akarca, Ulus Salih
    Ormeci, Necati
    Kaymakoglu, Sabahattin
    Aygen, Bilgehan
    Tozun, Nurdan
    Guner, Rahmet
    Bodur, Hurrem
    Lazarus, Jeffrey V.
    BMC HEALTH SERVICES RESEARCH, 2020, 20 (01)
  • [5] A Global Systematic Review of Hepatitis C Elimination Efforts through Micro-Elimination
    Lazarus, Jeffrey V.
    Picchio, Camila A.
    Byrne, Christopher J.
    Crespo, Javier
    Colombo, Massimo
    Cooke, Graham S.
    Dore, Gregory J.
    Grebely, Jason
    Ward, John W.
    Dillon, John F.
    SEMINARS IN LIVER DISEASE, 2022, 42 (02) : 159 - 172
  • [6] Updated Pathway to Micro-elimination of Hepatitis C Virus in the Hemodialysis Population
    Rajasekaran, Arun
    Franco, Ricardo A.
    Overton, Edgar T.
    McGuire, Brendan M.
    Towns, Graham C.
    Locke, Jayme E.
    Sawinski, Deirdre L.
    Bell, Emmy K.
    KIDNEY INTERNATIONAL REPORTS, 2021, 6 (07): : 1788 - 1798
  • [7] Micro-elimination of hepatitis C in patients with chronic kidney disease: an Egyptian single-center study
    Michael, Tari George
    Anwar, Christina A.
    Ahmed, Ossama A.
    Sarhan, Iman
    Elshazly, Yehia
    Shaker, Mohammed K.
    Eltabbakh, Mohammed
    Hashem, Walaa
    Tawfic, Safaa R.
    Kamel, Shimaa Y.
    Kandil, Doaa M.
    Naguib, Gina G.
    Khedr, Abdelrahman
    Ghanem, Eman A.
    Dabbous, Hany
    Doss, Wahid
    El-Sayed, Manal H.
    EGYPTIAN JOURNAL OF INTERNAL MEDICINE, 2022, 34 (01):
  • [8] Progress towards micro-elimination of hepatitis C in the custodial setting
    Gallacher, Jennifer
    McPherson, Stuart
    JOURNAL OF VIRAL HEPATITIS, 2021, 28 (02) : 300 - 301
  • [9] Results of a Hepatitis C Micro-Elimination Program in Two Addiction Centers Among Subjects With Substance Use Disorder
    Vega-Astudillo, Pablo
    Basurte-Villamor, Ignacio
    De Ema Lopez, Ines
    Olmos Espinos, Ruth
    Mesias-Perez, Beatriz
    Szerman, Nestor
    SUBSTANCE ABUSE-RESEARCH AND TREATMENT, 2022, 16
  • [10] The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational Considerations
    Lazarus, Jeffrey V.
    Safreed-Harmon, Kelly
    Thursz, Mark R.
    Dillon, John F.
    El-Sayed, Manal H.
    Elsharkawy, Ahmed M.
    Hatzakis, Angelos
    Jadoul, Michel
    Prestileo, Tullio
    Razavi, Homie
    Rockstroh, Juergen K.
    Wiktor, Stefan Z.
    Colombo, Massimo
    SEMINARS IN LIVER DISEASE, 2018, 38 (03) : 181 - 192